Genetic Predictors of Response to Oral Insulin for Type 1 Diabetes Prevention.

ABSTRACT:

Objective

The TrialNet Oral Insulin Prevention Trial TN07 tested oral insulin to prevent stage 3 type 1 diabetes (T1D) in 560 relatives with stage 1 T1D of individuals with T1D. Of the three predefined risk strata, participants in secondary stratum 1 (SS1) (n = 55), characterized by low first-phase insulin release, responded significantly better to oral insulin. We aimed to identify genetic factors associated with treatment response.

Research design and methods

The TEDDY-T1DExomeChip was used to genotype 552 participants with available DNA. Cox models examined associations between response to oral insulin and HLA haplotypes, 33 preselected T1D-associated single nucleotide polymorphisms, T1D genetic risk score 2 (GRS2), and type 2 diabetes (T2D)-associated polygenic scores. F

SUBMITTER: You L 

PROVIDER: S-EPMC12824796 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature